ArticleCancer immunology, immunotherapy : CII2020
CD160 expression on CD8
Article in Cancer immunology, immunotherapy : CII, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- CD160Cellular & molecular immunology · 2026Article
- Genetic variants ofFrontiers in immunology · 2026Article
- Histone methyltransferase DOT1L maintains cell state and restricts cytotoxic potential of CD8 T cells.Science advances · 2025Article
- Streptococcus lutetiensis inhibits CD8NPJ precision oncology · 2025Article
- Article
- Clinical Significance of TNFSF14/LIGHT and CD160 in Gastric Cancer and Peptic Ulcer Dyspepsia.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Emerging mechanisms of the unfolded protein response in therapeutic resistance: from chemotherapy to Immunotherapy.Cell communication and signaling : CCS · 2024Review
- CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment.Oncoimmunology · 2022Article
- Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.Oncoimmunology · 2022Article
- The Association Between Breast Cancer and Blood-Based Methylation ofFrontiers in genetics · 2022Article
- CD160 receptor in CLL: Current state and future avenues.Frontiers in immunology · 2022Review
- Features of repertoire diversity and gene expression in human cytotoxic T cells following allogeneic hematopoietic cell transplantation.Communications biology · 2021Article
- Expanded antigen-experienced CD160Journal for immunotherapy of cancer · 2021Article
- Tumor-infiltrating CD8Drug discovery today · 2021Review
- The Role of T Lymphocytes in the Pathogenesis of Paroxysmal Nocturnal Hemoglobinuria.Frontiers in immunology · 2021Review
- Distinct Molecular Subtypes of Diffuse Large B Cell Lymphoma Patients Treated with Rituximab-CHOP Are Associated with Different Clinical Outcomes and Molecular Mechanisms.BioMed research international · 2021Article
- Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD160 is an Ig-like glycoprotein expressed by the majority of circulating natural killer cells and γδ T cells. Whether CD160 could regulate CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.